Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53).

Journal Article (Journal Article)

BACKGROUND: A phase II study was conducted using concurrent paclitaxel, carboplatin, and external beam radiotherapy (RT) in patients with advanced head and neck cancer. METHODS: Forty-three patients (stage III, n = 12; stage IV, n = 31) were treated with 8 cycles of weekly paclitaxel (60 mg/m(2)), carboplatin (area under the curve [AUC] = 1), and RT (1.8 Gy daily; total dose, 66-72 Gy). Patients with initially palpable lymph nodes underwent neck dissection. RESULTS: The overall clinical response rate was 91% (65% complete, 26% partial). Severe mucositis occurred in 37 (90%) patients, necessitating hospitalization in 13 (31%) patients. With a median follow-up of 49 months, the locoregional and distant failure rates were 26% and 21%, respectively. CONCLUSIONS: Concurrent paclitaxel, carboplatin, and RT for advanced head and neck cancer results in high complete response rates. Long-term follow-up has revealed the curative potential of this regimen, though the doses used resulted in unacceptable toxicity.

Full Text

Duke Authors

Cited Authors

  • Chougule, PB; Akhtar, MS; Rathore, R; Koness, J; McRae, R; Nigri, P; Radie-Keane, K; Kennedy, T; Wanebo, HJ; Ready, N

Published Date

  • March 2008

Published In

Volume / Issue

  • 30 / 3

Start / End Page

  • 289 - 296

PubMed ID

  • 17657799

International Standard Serial Number (ISSN)

  • 1043-3074

Digital Object Identifier (DOI)

  • 10.1002/hed.20700


  • eng

Conference Location

  • United States